A Phase 2 interventional study of LY3549492 and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 49 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with obesity or overweight. Participation in the study will last about one year.
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's enrollment of 288 is above the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.
Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
W8M-MC-GN01:
W8M-MC-CWMM:
Have a BMI of
Exclusion Criteria:
W8M-MC-GN01:
W8M-MC-CWMM:
Have any of the following cardiovascular conditions within 3 months prior to screening:
Participants will receive LY3549492 orally
Drug: LY3549492
Participants will receive LY3549492 orally
Drug: LY3549492
Participants will receive LY3549492 orally
Drug: LY3549492
Participants will receive LY3549492 orally
Drug: LY3549492
Participants will receive LY3549492 orally
Drug: LY3549492
Participants will receive Placebo orally
Drug: Placebo
Administered orally
Administered orally
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 36
Change from Baseline in Body Weight (kilograms)
Time frame: Baseline, Week 36
Percentage of Participants who Achieve ≥5% Body Weight Reduction
Time frame: Baseline, Week 36
Percentage of Participants who Achieve ≥10% Body Weight Reduction
Time frame: Baseline, Week 36
Change from Baseline in Body Mass Index (BMI)
Time frame: Baseline, Week 36
Pharmacokinetics (PK): Average Concentration of LY3549492
Time frame: Week 36
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Sap, Csr
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company